Photo of Janice Gabrilove

Janice Gabrilove

  • PROFESSOR Oncological Sciences
  • PROFESSOR Medicine, Hematology and Medical Oncology
Print ProfilePrint Profile


  • Medical Oncology

  • American Board of Internal Medicine

Clinical Focus


  • MD, Mount Sinai School of Medicine

  • Residency, Internal Medicine
    Columbia-Presbyterian Medical Ctr.

  • Fellowship, Hematology/Oncology
    Memorial Sloan-Kettering


  • 2009 -
    Best Doctors
    New York Magazine


Role of Hematopoietic Factors in Normal Hematopoietic Cell Reconstitution

Dr. Gabrilove is a pioneer in the development of our understanding of the biology of hematopoietic growth factors and their clinical utility in promoting hematopoietic reconstitution. She is a co-inventor on the patent describing the initial isolation and characterization of human granulocyte colony stimulating factor (G-CSF), which is used in the treatment of chemotherapy induced myelosuppression and severe chronic neutropenia. Her initial studies also demonstrated the ability of G-CSF to mobilize progenitor cells into the peripheral blood (PBPC). This observation has revolutionized the way in which we perform marrow transplantation today, which is conducted almost exclusively utilizing G-CSF mobilized PBPC. This laboratory is currently investigating:

  • the development of novel therapeutic strategies in CLL; and
  • the role of arsenicals as experimental therapeutics to induce apoptosis.
  • Publications

    Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996; 87: 1056-1063.

    Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G. Filgrastim (r-metHuG-CSF.). The first ten years. Blood 1996; 88: 1907-1929.

    Jakubowski A, Gabrilove J. Granulocyte colony stimulating factor (G:CSF). Biology and clinical status. Cancer, Biotherapy & Radiopharmaceutics 1996; 11: 5-20.

    Konig A, Wrazel L, Warrell RP, Rivi R, Pandolfi PP, Jakubowski A, Gabrilove J. Comparative activity of melarsoprol and arsenic trioxide in chronic B cell leukemia lines. Blood 1997; 90: 562-570.

    Konig A, Menzel T, Lynen S, Rosen A, Raveche E, Gabrilove J. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997; 11: 258-272.

    Moskowitz CH, Stiff P, Gordon MS, McNiece I, Ho AD, Costa JJ, Broun ER, Bayer RA, Wyres M, Hill J, Jelaca-Maxwell K, Nichols CR, Brown SL, Nimer SD, Gabrilove J. Recombinant methionyl human stem cell factor (r-metHuSCF) and filgrastim for PBPC mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a phase I/II trial. Blood 1997; 89: 3136-3147.

    Shapiro R, Yao TJ, Moskowitz C, Reich L, Wuest DL, Heirnfeld S, McNiece IK, Gabrilove J, Nimer S, Moore MA. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells. Clin Cancer Res 1997; 3: 1571-1578.

    Wieder R, Wang H, Shike S, Wang Q, Menzel T, Feirt N, Jakubowski AA, Gabrilove J. Low level expression of basic FGF upregulates Bcl-2 and delays apoptosis, but high intracellular levels are required to induce transformation in NIH 3T3 cells. Growth Factors 1997; 15: 41-60.

    Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove J. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates bcl-2 and induces growth arrest and apoptosis in chronic B cell leukemia lines. Blood 1997; 90: 4307-4312.

    Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Scheinberg DA, Gabrilove J, Pandolfi PP, Warrell RP. Complete remission after induction of non-terminal differentiation and apoptosis in acute promyelocytic leukemia by arsenic trioxide. N Engl J Med 1998; 339: 1341-1348.

    Wang Z, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove J, Warrell RP, Pandolfi PP. Aresnic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARa independent manner. Blood 1998; 92: 1497-1504.

    Xu Y, Lai LT, Gabrilove J, Scheinberg DA. Antitumor activity of actinoniun in vitro and in vivo. Clin Cancer Res 1998; 4: 171-176.

    Waltzman RJ, Gabrilove J. Challenges of treating cancer-related fatigue. Oncology Special Edition 2000; 3: 129-132.

    Gabrilove J, Einhorn L, Cleeland C, Livingston R, Weiner E, Waltzman RJ. Efficacy of a once-weekly dosage regimen of epoetin alfa in hematologic malignancies. International Society of Hematology 2000 Supplement 1; 72: 55.

    Industry Relationships

    Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

    Below are financial relationships with industry reported by Dr. Gabrilove during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

    Royalty Payments:

    • Amgen Inc.; Cephalon, Inc.

    Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

    Insurance Information

    Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

    Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

    Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

    Edit profile in Sinai Central


    Atran Berg Laboratory Building Room 6-16
    1428 Madison Avenue
    New York, NY 10029

    Tel: 212-241-9650
    Fax: 212-289-0678
    Ruttenberg Treatment Center

    1470 Madison Avenue
    3rd Floor
    New York, NY 10029

    Tel: 212-241-6756
    Fax: 212-289-0678
    Get Directions
    Insurance Plans
    • 1199
    • Access Meicare
    • Aetna
    • Affinity
    • Amerigroup
    • AmidaCare
    • CIGNA - Indemnity
    • Empire Blue Cross/Blue Shield
    • Fidelis Care NY
    • GHI
    • HIP Commercial
    • HealthFirst
    • Humana
    • Island Group
    • Magnacare
    • Medicaid of New York
    • Medicare
    • MetroPlus Health Plan
    • MultiPlan, Inc.
    • Oxford Health Plans
    • Pomco
    • United Healthcare
    • VNS Medicare
    • WellCare of New York, Inc.
    Payment Methods
    • Master Card
    • Visa
    • American Express
    • Discover
    • Personal Check
    • Cash